David Moreno
Concepts (309)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Waldenstrom Macroglobulinemia | 7 | 2025 | 20 | 3.680 |
Why?
| | Multiple Myeloma | 14 | 2026 | 309 | 3.120 |
Why?
| | Monoclonal Gammopathy of Undetermined Significance | 4 | 2025 | 11 | 2.590 |
Why?
| | Lymphoma, B-Cell | 3 | 2023 | 141 | 2.020 |
Why?
| | Saccharomyces cerevisiae | 13 | 2025 | 574 | 1.990 |
Why?
| | Saccharomyces cerevisiae Proteins | 11 | 2025 | 414 | 1.930 |
Why?
| | B-Cell Maturation Antigen | 7 | 2026 | 17 | 1.570 |
Why?
| | Immunotherapy, Adoptive | 9 | 2026 | 343 | 1.510 |
Why?
| | Myeloid Differentiation Factor 88 | 5 | 2025 | 119 | 1.490 |
Why?
| | Proteostasis | 2 | 2020 | 27 | 1.220 |
Why?
| | Cellular Senescence | 3 | 2024 | 226 | 1.210 |
Why?
| | Immunoglobulin M | 5 | 2025 | 265 | 1.200 |
Why?
| | Molecular Chaperones | 3 | 2019 | 199 | 1.140 |
Why?
| | Plasmacytoma | 2 | 2022 | 19 | 0.910 |
Why?
| | Chromosomes, Human, Pair 14 | 1 | 2025 | 23 | 0.880 |
Why?
| | Chromosomes, Human, Pair 11 | 1 | 2025 | 59 | 0.870 |
Why?
| | Translocation, Genetic | 1 | 2025 | 120 | 0.830 |
Why?
| | Chromosome Aberrations | 1 | 2025 | 166 | 0.820 |
Why?
| | Cell-Free Nucleic Acids | 1 | 2022 | 34 | 0.710 |
Why?
| | Calcaneus | 1 | 2022 | 31 | 0.710 |
Why?
| | Pharmaceutical Preparations | 2 | 2020 | 171 | 0.700 |
Why?
| | Galactokinase | 1 | 2020 | 3 | 0.660 |
Why?
| | Sarcoma, Ewing | 1 | 2022 | 103 | 0.660 |
Why?
| | Epistasis, Genetic | 1 | 2020 | 64 | 0.630 |
Why?
| | Automation | 1 | 2020 | 104 | 0.630 |
Why?
| | Cell Enlargement | 2 | 2019 | 8 | 0.620 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2025 | 699 | 0.600 |
Why?
| | Leishmania infantum | 4 | 2014 | 8 | 0.600 |
Why?
| | Bone Neoplasms | 1 | 2022 | 265 | 0.600 |
Why?
| | DNA Replication | 2 | 2023 | 249 | 0.590 |
Why?
| | G1 Phase Cell Cycle Checkpoints | 1 | 2019 | 8 | 0.590 |
Why?
| | High-Throughput Screening Assays | 2 | 2020 | 177 | 0.590 |
Why?
| | Graft vs Host Disease | 2 | 2019 | 279 | 0.580 |
Why?
| | Cell Cycle Checkpoints | 1 | 2019 | 97 | 0.580 |
Why?
| | Histone Deacetylases | 1 | 2020 | 207 | 0.580 |
Why?
| | Cell Size | 1 | 2019 | 93 | 0.570 |
Why?
| | Time-Lapse Imaging | 1 | 2019 | 21 | 0.570 |
Why?
| | Intravital Microscopy | 1 | 2019 | 24 | 0.570 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2025 | 1969 | 0.550 |
Why?
| | Heat-Shock Response | 1 | 2019 | 77 | 0.550 |
Why?
| | Chromatin | 2 | 2025 | 553 | 0.520 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2019 | 783 | 0.410 |
Why?
| | Receptors, Immunologic | 2 | 2025 | 209 | 0.400 |
Why?
| | Carbamates | 2 | 2010 | 50 | 0.390 |
Why?
| | Mutation | 5 | 2025 | 4090 | 0.370 |
Why?
| | Cyclins | 4 | 2021 | 79 | 0.360 |
Why?
| | Smoldering Multiple Myeloma | 2 | 2021 | 9 | 0.350 |
Why?
| | Imides | 1 | 2010 | 5 | 0.330 |
Why?
| | Antiprotozoal Agents | 1 | 2010 | 15 | 0.320 |
Why?
| | Receptors, CXCR4 | 2 | 2022 | 91 | 0.320 |
Why?
| | T-Lymphocytes | 3 | 2025 | 1998 | 0.320 |
Why?
| | Selenium | 1 | 2010 | 50 | 0.320 |
Why?
| | CDC28 Protein Kinase, S cerevisiae | 2 | 2021 | 7 | 0.320 |
Why?
| | Humans | 44 | 2026 | 145785 | 0.310 |
Why?
| | Prognosis | 3 | 2025 | 4330 | 0.290 |
Why?
| | Dexamethasone | 2 | 2025 | 365 | 0.290 |
Why?
| | Genomics | 2 | 2025 | 830 | 0.280 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2024 | 883 | 0.270 |
Why?
| | HSP40 Heat-Shock Proteins | 2 | 2019 | 25 | 0.270 |
Why?
| | Neoplasm, Residual | 2 | 2026 | 143 | 0.260 |
Why?
| | Small Molecule Libraries | 2 | 2020 | 111 | 0.250 |
Why?
| | Skin Neoplasms | 2 | 2023 | 853 | 0.250 |
Why?
| | POEMS Syndrome | 1 | 2026 | 3 | 0.240 |
Why?
| | Gene Expression Regulation, Fungal | 3 | 2023 | 78 | 0.240 |
Why?
| | CD28 Antigens | 1 | 2026 | 59 | 0.230 |
Why?
| | Protein Biosynthesis | 4 | 2022 | 452 | 0.230 |
Why?
| | Signaling Lymphocytic Activation Molecule Family | 1 | 2025 | 7 | 0.230 |
Why?
| | Cytokinesis | 1 | 2025 | 50 | 0.220 |
Why?
| | Positive Regulatory Domain I-Binding Factor 1 | 1 | 2025 | 17 | 0.220 |
Why?
| | Hyperpigmentation | 1 | 2005 | 27 | 0.220 |
Why?
| | Bortezomib | 1 | 2025 | 54 | 0.220 |
Why?
| | Sulfonamides | 2 | 2024 | 583 | 0.220 |
Why?
| | Thalidomide | 1 | 2025 | 43 | 0.210 |
Why?
| | Aged | 11 | 2026 | 26217 | 0.210 |
Why?
| | Antineoplastic Agents | 3 | 2024 | 2219 | 0.210 |
Why?
| | Histone Acetyltransferases | 1 | 2025 | 57 | 0.210 |
Why?
| | DNA Helicases | 1 | 2025 | 136 | 0.210 |
Why?
| | Middle Aged | 13 | 2026 | 36309 | 0.210 |
Why?
| | Receptors, Virus | 1 | 2024 | 95 | 0.200 |
Why?
| | Remote Consultation | 1 | 2005 | 66 | 0.200 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2025 | 161 | 0.200 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2025 | 118 | 0.200 |
Why?
| | Bone Marrow | 2 | 2024 | 307 | 0.200 |
Why?
| | Protein Kinase Inhibitors | 2 | 2024 | 981 | 0.200 |
Why?
| | Cell Cycle | 3 | 2023 | 598 | 0.200 |
Why?
| | Xenograft Model Antitumor Assays | 5 | 2026 | 936 | 0.200 |
Why?
| | Aged, 80 and over | 6 | 2025 | 8347 | 0.200 |
Why?
| | Male | 20 | 2026 | 73012 | 0.200 |
Why?
| | Disease-Free Survival | 2 | 2022 | 770 | 0.190 |
Why?
| | Cell Line, Tumor | 6 | 2026 | 3551 | 0.190 |
Why?
| | Quinazolines | 1 | 2024 | 266 | 0.190 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2024 | 224 | 0.180 |
Why?
| | Immunoglobulin Light-chain Amyloidosis | 1 | 2021 | 10 | 0.180 |
Why?
| | Models, Molecular | 5 | 2020 | 1599 | 0.180 |
Why?
| | Cell Cycle Proteins | 2 | 2023 | 630 | 0.170 |
Why?
| | Peptide Elongation Factor 1 | 1 | 2021 | 10 | 0.170 |
Why?
| | Drug Discovery | 2 | 2020 | 153 | 0.170 |
Why?
| | Signal Transduction | 3 | 2025 | 5226 | 0.170 |
Why?
| | Molecular Dynamics Simulation | 2 | 2020 | 265 | 0.170 |
Why?
| | Skin Diseases | 2 | 2018 | 152 | 0.170 |
Why?
| | Immunoglobulin Light Chains | 1 | 2021 | 52 | 0.170 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 2021 | 86 | 0.170 |
Why?
| | Allografts | 1 | 2022 | 152 | 0.170 |
Why?
| | Cytoplasmic Granules | 1 | 2021 | 60 | 0.170 |
Why?
| | Endodeoxyribonucleases | 2 | 2014 | 77 | 0.160 |
Why?
| | Female | 19 | 2026 | 79045 | 0.160 |
Why?
| | Genes, Regulator | 1 | 2020 | 35 | 0.160 |
Why?
| | Patient Selection | 1 | 2005 | 739 | 0.160 |
Why?
| | Polymerase Chain Reaction | 2 | 2022 | 1043 | 0.160 |
Why?
| | Dendritic Spines | 1 | 2021 | 70 | 0.160 |
Why?
| | Hydroxamic Acids | 1 | 2020 | 94 | 0.160 |
Why?
| | Models, Biological | 3 | 2024 | 1764 | 0.160 |
Why?
| | Calibration | 1 | 2020 | 152 | 0.160 |
Why?
| | Feedback, Physiological | 1 | 2020 | 80 | 0.160 |
Why?
| | Epigenomics | 1 | 2020 | 117 | 0.150 |
Why?
| | Melanoma | 2 | 2024 | 762 | 0.150 |
Why?
| | Biomarkers | 3 | 2026 | 4302 | 0.150 |
Why?
| | Niacinamide | 1 | 2020 | 104 | 0.150 |
Why?
| | Photopheresis | 1 | 2019 | 9 | 0.150 |
Why?
| | S Phase Cell Cycle Checkpoints | 1 | 2019 | 4 | 0.150 |
Why?
| | RNA, Messenger | 2 | 2025 | 2805 | 0.150 |
Why?
| | Cell Nucleolus | 1 | 2019 | 20 | 0.150 |
Why?
| | Sepsis | 1 | 2026 | 664 | 0.150 |
Why?
| | Diagnosis, Differential | 2 | 2026 | 1512 | 0.150 |
Why?
| | Luminescent Agents | 1 | 2019 | 7 | 0.140 |
Why?
| | Treatment Outcome | 5 | 2025 | 11794 | 0.140 |
Why?
| | Spatio-Temporal Analysis | 1 | 2019 | 34 | 0.140 |
Why?
| | Actins | 1 | 2021 | 426 | 0.140 |
Why?
| | Acute Disease | 2 | 2019 | 1036 | 0.140 |
Why?
| | Cyclin G1 | 1 | 2018 | 1 | 0.140 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2022 | 411 | 0.140 |
Why?
| | Cell Growth Processes | 1 | 2018 | 48 | 0.140 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2019 | 75 | 0.140 |
Why?
| | Transcription, Genetic | 1 | 2025 | 1454 | 0.140 |
Why?
| | Spectrometry, Fluorescence | 1 | 2019 | 165 | 0.140 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2022 | 1150 | 0.140 |
Why?
| | Lymphoma | 1 | 2020 | 241 | 0.140 |
Why?
| | Cyclin-Dependent Kinases | 1 | 2019 | 122 | 0.130 |
Why?
| | Gene Regulatory Networks | 1 | 2020 | 318 | 0.130 |
Why?
| | Centromere | 1 | 2018 | 61 | 0.130 |
Why?
| | Adenosine Triphosphatases | 1 | 2019 | 159 | 0.130 |
Why?
| | Luminescent Proteins | 1 | 2019 | 186 | 0.130 |
Why?
| | Stress, Physiological | 1 | 2021 | 443 | 0.130 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 2019 | 194 | 0.130 |
Why?
| | Biological Evolution | 1 | 2020 | 468 | 0.120 |
Why?
| | Macrophages | 1 | 2024 | 1507 | 0.120 |
Why?
| | Pleural Effusion | 1 | 2017 | 59 | 0.120 |
Why?
| | Mice | 8 | 2026 | 18358 | 0.120 |
Why?
| | Adult | 9 | 2026 | 40882 | 0.120 |
Why?
| | Chronic Disease | 2 | 2019 | 1812 | 0.110 |
Why?
| | Epigenesis, Genetic | 1 | 2020 | 693 | 0.110 |
Why?
| | Disease Management | 3 | 2025 | 653 | 0.110 |
Why?
| | Recombinant Proteins | 1 | 2019 | 1368 | 0.110 |
Why?
| | Antibodies, Monoclonal | 1 | 2022 | 1505 | 0.110 |
Why?
| | Endoplasmic Reticulum | 1 | 2017 | 264 | 0.110 |
Why?
| | Mitochondria | 2 | 2014 | 994 | 0.110 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2015 | 136 | 0.110 |
Why?
| | DNA-Binding Proteins | 1 | 2022 | 1482 | 0.100 |
Why?
| | Molecular Conformation | 3 | 2020 | 141 | 0.100 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2015 | 172 | 0.100 |
Why?
| | Endonucleases | 1 | 2014 | 34 | 0.100 |
Why?
| | Exonucleases | 1 | 2014 | 10 | 0.100 |
Why?
| | HIV Infections | 3 | 2019 | 3195 | 0.100 |
Why?
| | NADH, NADPH Oxidoreductases | 1 | 2013 | 23 | 0.100 |
Why?
| | Pyridones | 1 | 2015 | 209 | 0.090 |
Why?
| | Apoptosis | 2 | 2014 | 2445 | 0.090 |
Why?
| | Glucocorticoids | 1 | 2017 | 532 | 0.090 |
Why?
| | Disease Models, Animal | 4 | 2025 | 4568 | 0.090 |
Why?
| | Recurrence | 2 | 2026 | 1139 | 0.090 |
Why?
| | Immunoglobulin A | 2 | 2025 | 214 | 0.090 |
Why?
| | Animals | 9 | 2026 | 38106 | 0.090 |
Why?
| | HeLa Cells | 2 | 2025 | 632 | 0.090 |
Why?
| | Incidence | 1 | 2018 | 2934 | 0.090 |
Why?
| | Parasitic Sensitivity Tests | 1 | 2010 | 3 | 0.080 |
Why?
| | Inhibitory Concentration 50 | 1 | 2010 | 91 | 0.080 |
Why?
| | Transplantation, Autologous | 2 | 2022 | 301 | 0.080 |
Why?
| | Anti-HIV Agents | 2 | 2010 | 912 | 0.080 |
Why?
| | HIV | 2 | 2010 | 251 | 0.080 |
Why?
| | History, 21st Century | 2 | 2021 | 222 | 0.080 |
Why?
| | Gene Expression | 2 | 2019 | 1478 | 0.080 |
Why?
| | History, 20th Century | 2 | 2021 | 328 | 0.070 |
Why?
| | Structure-Activity Relationship | 2 | 2024 | 563 | 0.070 |
Why?
| | Organophosphates | 1 | 2010 | 179 | 0.070 |
Why?
| | Child | 5 | 2022 | 22740 | 0.070 |
Why?
| | Adolescent | 4 | 2022 | 22577 | 0.070 |
Why?
| | Spain | 3 | 2019 | 50 | 0.070 |
Why?
| | Protozoan Proteins | 1 | 2008 | 90 | 0.070 |
Why?
| | Cell Survival | 1 | 2010 | 1105 | 0.060 |
Why?
| | Peptides | 1 | 2013 | 1000 | 0.060 |
Why?
| | Aurora Kinase B | 1 | 2025 | 10 | 0.060 |
Why?
| | Biomarkers, Tumor | 2 | 2024 | 1329 | 0.060 |
Why?
| | Chromosome Segregation | 1 | 2025 | 45 | 0.060 |
Why?
| | Bronchogenic Cyst | 1 | 2005 | 8 | 0.060 |
Why?
| | Remission Induction | 1 | 2026 | 306 | 0.060 |
Why?
| | Cell Nucleus | 1 | 2008 | 588 | 0.060 |
Why?
| | Mice, SCID | 1 | 2026 | 369 | 0.050 |
Why?
| | Cell Line | 1 | 2010 | 2823 | 0.050 |
Why?
| | Mouse Embryonic Stem Cells | 1 | 2025 | 36 | 0.050 |
Why?
| | Nectins | 1 | 2024 | 7 | 0.050 |
Why?
| | Hepatitis C | 1 | 2007 | 256 | 0.050 |
Why?
| | Time Factors | 2 | 2017 | 7134 | 0.050 |
Why?
| | RNA Stability | 1 | 2025 | 107 | 0.050 |
Why?
| | CRISPR-Cas Systems | 1 | 2025 | 166 | 0.050 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2005 | 237 | 0.050 |
Why?
| | Mice, Inbred NOD | 1 | 2025 | 616 | 0.050 |
Why?
| | Basic-Leucine Zipper Transcription Factors | 1 | 2023 | 43 | 0.050 |
Why?
| | RNA Splicing | 1 | 2025 | 284 | 0.050 |
Why?
| | HIV-1 | 2 | 2010 | 908 | 0.050 |
Why?
| | Blood-Brain Barrier | 1 | 2024 | 160 | 0.050 |
Why?
| | Mice, Nude | 1 | 2024 | 680 | 0.050 |
Why?
| | Biological Transport | 1 | 2023 | 424 | 0.050 |
Why?
| | Longevity | 1 | 2023 | 178 | 0.040 |
Why?
| | Antiretroviral Therapy, Highly Active | 3 | 2010 | 279 | 0.040 |
Why?
| | Rats | 2 | 2024 | 5585 | 0.040 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2022 | 155 | 0.040 |
Why?
| | Child, Preschool | 4 | 2017 | 11868 | 0.040 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2021 | 224 | 0.040 |
Why?
| | Trans-Activators | 1 | 2023 | 396 | 0.040 |
Why?
| | Single-Cell Analysis | 1 | 2024 | 361 | 0.040 |
Why?
| | Th17 Cells | 1 | 2022 | 102 | 0.040 |
Why?
| | Cellular Microenvironment | 1 | 2021 | 94 | 0.040 |
Why?
| | Iron | 1 | 2023 | 359 | 0.040 |
Why?
| | Forkhead Transcription Factors | 1 | 2022 | 209 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2021 | 5428 | 0.040 |
Why?
| | Intrinsically Disordered Proteins | 1 | 2021 | 42 | 0.040 |
Why?
| | Actin Cytoskeleton | 1 | 2021 | 103 | 0.040 |
Why?
| | Neoplasm Grading | 1 | 2021 | 311 | 0.040 |
Why?
| | Inflammasomes | 1 | 2022 | 144 | 0.040 |
Why?
| | Databases, Protein | 1 | 2020 | 88 | 0.040 |
Why?
| | Molecular Weight | 1 | 2020 | 312 | 0.040 |
Why?
| | Quantum Theory | 1 | 2020 | 86 | 0.040 |
Why?
| | Neoadjuvant Therapy | 1 | 2023 | 467 | 0.040 |
Why?
| | Carcinogenesis | 1 | 2021 | 228 | 0.040 |
Why?
| | Blood Viscosity | 1 | 2019 | 19 | 0.040 |
Why?
| | Proteasome Inhibitors | 1 | 2019 | 41 | 0.040 |
Why?
| | Public Health Surveillance | 1 | 2019 | 83 | 0.040 |
Why?
| | Glucose | 1 | 2024 | 1050 | 0.040 |
Why?
| | Colitis | 1 | 2022 | 281 | 0.040 |
Why?
| | Mortality | 1 | 2021 | 381 | 0.040 |
Why?
| | Repressor Proteins | 1 | 2022 | 429 | 0.040 |
Why?
| | Antibiotic Prophylaxis | 1 | 2020 | 134 | 0.040 |
Why?
| | Neuronal Plasticity | 1 | 2021 | 305 | 0.030 |
Why?
| | Disease Progression | 2 | 2021 | 2865 | 0.030 |
Why?
| | Ligands | 1 | 2020 | 668 | 0.030 |
Why?
| | G1 Phase | 1 | 2018 | 65 | 0.030 |
Why?
| | Rituximab | 1 | 2019 | 210 | 0.030 |
Why?
| | CD4 Lymphocyte Count | 2 | 2010 | 280 | 0.030 |
Why?
| | Survival Analysis | 1 | 2021 | 1378 | 0.030 |
Why?
| | Saccharomycetales | 1 | 2018 | 29 | 0.030 |
Why?
| | Immunotherapy | 1 | 2023 | 668 | 0.030 |
Why?
| | Lymphocyte Activation | 1 | 2022 | 1133 | 0.030 |
Why?
| | Piperidines | 1 | 2019 | 222 | 0.030 |
Why?
| | Proteolysis | 1 | 2018 | 172 | 0.030 |
Why?
| | Anti-Bacterial Agents | 2 | 2020 | 1925 | 0.030 |
Why?
| | Neoplasm Staging | 1 | 2021 | 1475 | 0.030 |
Why?
| | Amino Acid Sequence | 2 | 2013 | 2131 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2021 | 892 | 0.030 |
Why?
| | Adenine | 1 | 2019 | 339 | 0.030 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2021 | 1217 | 0.030 |
Why?
| | Cell Division | 1 | 2018 | 757 | 0.030 |
Why?
| | Computational Biology | 1 | 2021 | 669 | 0.030 |
Why?
| | Molecular Sequence Data | 2 | 2013 | 2883 | 0.030 |
Why?
| | Viral Load | 2 | 2010 | 526 | 0.030 |
Why?
| | Gene Expression Regulation | 1 | 2025 | 2601 | 0.030 |
Why?
| | Membrane Glycoproteins | 1 | 2018 | 499 | 0.030 |
Why?
| | Pyrimidines | 1 | 2019 | 530 | 0.030 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2021 | 1450 | 0.030 |
Why?
| | Cohort Studies | 2 | 2021 | 6033 | 0.030 |
Why?
| | Pyrazoles | 1 | 2019 | 517 | 0.030 |
Why?
| | Transcription Factors | 1 | 2023 | 1736 | 0.030 |
Why?
| | Community-Acquired Infections | 1 | 2017 | 177 | 0.030 |
Why?
| | Protein Binding | 1 | 2021 | 2240 | 0.030 |
Why?
| | C-Reactive Protein | 1 | 2017 | 423 | 0.030 |
Why?
| | Databases, Factual | 1 | 2020 | 1491 | 0.030 |
Why?
| | Proteins | 1 | 2020 | 1023 | 0.030 |
Why?
| | Retrospective Studies | 3 | 2019 | 17330 | 0.030 |
Why?
| | Survival Rate | 1 | 2019 | 2094 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2017 | 1043 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2022 | 2050 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2017 | 1330 | 0.020 |
Why?
| | Crystallography, X-Ray | 1 | 2015 | 486 | 0.020 |
Why?
| | Nuclear Proteins | 1 | 2018 | 740 | 0.020 |
Why?
| | Phenotype | 1 | 2021 | 3170 | 0.020 |
Why?
| | Recovery of Function | 1 | 2017 | 716 | 0.020 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2013 | 376 | 0.020 |
Why?
| | Administration, Oral | 1 | 2015 | 867 | 0.020 |
Why?
| | Neurons | 1 | 2021 | 1652 | 0.020 |
Why?
| | Protein Multimerization | 1 | 2013 | 205 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2017 | 2064 | 0.020 |
Why?
| | Brain | 1 | 2024 | 2969 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2933 | 0.020 |
Why?
| | Pneumonia | 1 | 2017 | 636 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2022 | 5995 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2015 | 2028 | 0.020 |
Why?
| | Furans | 1 | 2010 | 26 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2010 | 428 | 0.020 |
Why?
| | Protein Sorting Signals | 1 | 2008 | 21 | 0.020 |
Why?
| | Prospective Studies | 1 | 2021 | 8078 | 0.020 |
Why?
| | Deoxyribonucleases | 1 | 2008 | 24 | 0.020 |
Why?
| | Sequence Alignment | 1 | 2008 | 362 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2015 | 2514 | 0.020 |
Why?
| | Protein Transport | 1 | 2008 | 442 | 0.020 |
Why?
| | Pregnancy | 1 | 2019 | 7216 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2008 | 855 | 0.010 |
Why?
| | RNA, Viral | 1 | 2010 | 693 | 0.010 |
Why?
| | Hepacivirus | 1 | 2007 | 242 | 0.010 |
Why?
| | Risk Factors | 1 | 2019 | 10919 | 0.010 |
Why?
| | Clinical Trials as Topic | 1 | 2005 | 1062 | 0.010 |
Why?
| | Infant | 1 | 2007 | 10091 | 0.010 |
Why?
|
|
Moreno's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|